Marcelina Kaleta, Joanna Zawitkowska, Jerzy R. Kowalczyk and Tomasz Olcha
acutelymphoblasticleukemia. Med Sci Monit 2015;21:1656–61. 10.12659/MSM.893142
Yang L Yu L Chen X Hu Y Wang B Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acutelymphoblasticleukemia Med Sci Monit 2015 21 1656 – 61
 Ceppi F, Langlois-Pelletier C, Gagné V, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acutelymphoblasticleukemia. Pharmacogenomics 2014;15(8):1105–16. 10.2217/pgs.14.68
Ceppi F Langlois-Pelletier C Gagné V et al
Marta Masternak, Joanna Knap and Krzysztof Giannopoulos
the patients without VTE (median 7.2 fL, p = 0.034). Patients with baseline MPV 6.8 fL or below more often developed VTE compared to patients with higher MPV values (19% vs. 5.5%, p = 0.0244). Of the HL patients, in both the univariate and multivariate models, the patients with baseline low MPV levels had an above twofold increased risk of VTE development [ 29 ].
There are also reports about the prognostic role of platelet parameters in acutelymphoblasticleukemia (ALL) in pediatric patients [ 30 , 31 ]. ALL is the most common type of cancer
Overall cumulative incidence of infections in pediatric hematology and oncology (PHO) and pediatric hematopoietic stem cell transplantation (HCT) settings between 2012 and 2017: (A and B) including possible, probable, and proven IFD; (C and D) including probable and proven but not possible IFD
Infections in pediatric hematology and oncology setting
The analysis included 1363 patients, with newly diagnosed ALL (2012–2017). The patients received therapy according to the ALL IC-BFM 2002 and 2009 (Intercontinental
Iwona Hus, Agnieszka Piekarska, Jacek Roliński, Katarzyna Brzeźniakiewicz-Janus, Krzysztof Giannopoulos, Krzysztof Jamroziak, Beata Piątkowska-Jakubas, Agnieszka Wierzbowska, Jan Maciej Zaucha, Sebastian Giebel, Tadeusz Robak and Lidia Gil
Orenstein WA Ofifit PA Vaccine 6th ed Saunders, Philadelphia 2013
 Saghafian-Hedengren S, Söderström I, Sverremark-Ekström E, et al. Insights into defective serological memory after acutelymphoblasticleukaemia treatment: The role of the plasma cell survival niche, memory B-cells and gut microbiota in vaccine responses. Blood Rev 2018;32:71–80. 10.1016/j.blre.2017.08.009
Saghafian-Hedengren S Söderström I Sverremark-Ekström E Insights into defective serological memory after acutelymphoblasticleukaemia treatment: The role of the plasma
Samia Abd El-Moneim Ebied, Nadia Aly Sadek, Nadia El-Sayed Zaki, Samir Ali Abd El- Kaream and Heba Khafagui Ahmed El Kashif
accumulation of blast cells in the bone marrow and peripheral blood [ 12 ]. Acutelymphoblasticleukemia (ALL) is a malignant disease characterized by the accumulation of lymphoblasts and it may be B or T lineages and the first attempt at classifying ALL was the French-American-British (FAB) morphological criteria that divided ALL into 3 subtypes (L1, L2 and L3) based on cell size, cytoplasm, nucleoli, vacuolation and basophilia. In 1997, the World Health Organization proposed a composite classification in an attempt to account for morphology and cytogenetic profile of the
Amina H Hassab, Dalia A Nafea, Rania S Swelem and Basma M Ghazal
receptor induces T-cell proliferation and differentiation [ 8 ].
Recent research has described CD25 as a poor prognostic factor in acutelymphoblasticleukemia [ 9 ]. Moreover, in AML, previously published data from small retrospective studies have suggested an unfavorable impact of CD25 [ 10 , 11 ].
Therefore, our aim was to evaluate the expression of CD25 in adult Egyptian patients with newly diagnosed AML and thereafter study its impact on prognosis.
Subjects and methods
The current study was conducted with 50 newly diagnosed adult AML patients before
Łukasz Klasa, Alicja Sadowska-Klasa, Agnieszka Piekarska, Magdalena Dutka, Maria Bieniaszewska, Dariusz Wydra and Jan Maciej Zaucha
preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 2013 31 19 2500 – 10 10.1200/JCO.2013.49.2678
 Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acutelymphoblasticleukemia is potentially unsafe. Blood 2010;116(16):2908–14. 10.1182/blood-2010-01-265751
Dolmans MM Marinescu C Saussoy P Van Langendonckt A Amorim C Donnez J Reimplantation of cryopreserved ovarian tissue from
younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia 2017; 31(1):34–39. 10.1038/leu.2016.252
Blum W Sanford BL Klisovic R Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503) Leukemia 2017 31 1 34 39
 Desjonquères A, Chevallier P, Thomas X, et al. Acutelymphoblasticleukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study
Agnieszka Pluta, Tadeusz Robak, Kamil Brzozowski, Barbara Cebula-Obrzut, Agata Majchrzak, Piotr Pluta, Anna Szmigielska-Kapłon, Olga Grzybowska-Izydorczyk, Magdalena Czemerska, Piotr Stelmach, Piotr Smolewski and Agnieszka Wierzbowska
Nakagawa et al. studied NAIP mRNA expression in BM samples from 13 healthy individuals, 9 patients with AML, 7 with acutelymphoblasticleukemia (ALL) and 8 with acute mixed linage leukemia (AMLL) by quantitative RT-PCR. They found that NAIP expression was present in all examined cases and was higher in AML, ALL, and AMLL than in healthy BM samples [ 26 ].
The present study is the first to assess the expression of NAIP protein in AML cells using cytometry. It identified NAIP expression in 98% of AML patients with a range 1–79.6%. The presence of NAIP mRNA
Mateusz Nowicki, Piotr Stelmach and Anna Szmigielska-Kapłon
mRNA degradation? The deepening mystery of microRNA function Cell Res 2012 9 1322 4 10.1038/cr.2012.80
 Fan SJ, Li HB, Cui G, et al. miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acutelymphoblasticleukemia. Leuk Res 2016;41:62–70. doi: 10.1016/j. leukres.2015.11.016. 10.1016/j.leukres.2015.11.016
Fan SJ Li HB Cui G miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acutelymphoblasticleukemia Leuk Res 2016 41 62 70 10.1016/j.leukres.2015